Peptide Dosing Chart for Weight Loss: GH, AOD, CJC, Sema | FormBlends

Trust signals

> Written by the FormBlends Medical Content Team · Fact-checked against cited primary sources · Last updated May 2026

Key Takeaways

What is a practical peptide dosing chart for weight loss?

Table of contents

1. Evidence ledger: how strong is each compound's fat-loss data?
2. Peptide dosage chart for weight loss (the main reference table)
3. HGH dosage for weight loss: what the clinical literature actually shows
4. How to structure a fat loss peptide cycle
5. Lipo-C peptide dosage for weight loss: what is actually in it?
6. What most pages get wrong about peptide dosing
7. Chemistry: why peptide stability rules are not optional
8. Honest head-to-head: peptides vs. approved options
9. Operational label literacy: reading a COA and doing reconstitution math
10. FAQ
11. Sources

Evidence ledger: how strong is each compound's fat-loss data?

Peptide dosage chart for weight loss (the main reference table)

HGH dosage for weight loss: what the clinical literature actually shows

Exogenous recombinant human growth hormone (rhGH) has been studied for fat loss in adults without confirmed GH deficiency. A meta-analysis by Jorgensen et al. (published in the Annals of Internal Medicine, 1994) and subsequent reviews found that rhGH reduced fat mass but at doses that produced meaningful adverse effects. Common research doses range from approximately 0.01 to 0.03 mg per kg per day subcutaneously.

The specific side-effect profile at those doses includes fluid retention, carpal tunnel syndrome, arthralgias, and measurable worsening of fasting insulin sensitivity. The 2003 FDA approval of rhGH for adult GH deficiency uses lower, individualized doses than the fat-loss studies. Using exogenous HGH outside confirmed deficiency is off-label and carries meaningful metabolic risk. GH secretagogues are often described as a safer alternative because they stimulate endogenous pulse release rather than bypassing the hypothalamic-pituitary axis, but that benefit is theoretical in the absence of comparative clinical trials.

How to structure a fat loss peptide cycle

The concept of "cycling" applies to GH secretagogues and AOD-9604, not to GLP-1 agonists, which are prescribed as continuous therapy.

GH secretagogue cycle structure (research context):

• Weeks 1 to 2: Start at the lower end of the dose range to assess tolerability (e.g., 100 mcg ipamorelin once daily).
• Weeks 3 to 12: Progress to target dose and standard frequency. Timing injections 30 to 45 minutes before fasted cardio or at bedtime aligns with natural GH pulsatility, though this timing optimization has no human RCT confirmation.
• Weeks 13 to 16 (off cycle): Allow the GHS receptor (GHSR-1a) and GHRH receptor to resensitize. Extended continuous use is associated with receptor downregulation in animal models.
• Key dietary rule: GH secretion is blunted by hyperinsulinemia. Injecting GHRPs or GHRHs within 60 to 90 minutes of a carbohydrate-rich meal reduces GH pulse amplitude in human studies (Arvat et al., 2001).

GLP-1 agonist protocol (no cycling): Titrate per the prescriber's escalation schedule and maintain. Discontinuation leads to weight regain in the majority of patients within weeks to months, per post-STEP extension data. These are chronic medications, not cycles.

Lipo-C peptide dosage for weight loss: what is actually in it?

Lipo-C is not a peptide. The name causes significant search confusion. A typical compounded lipo-C injection contains methionine, inositol, choline (the "MIC" base), plus cyanocobalamin (B12), and sometimes L-carnitine, thiamine, or riboflavin. There is no peptide molecule in a standard lipo-C formulation.

Methionine is an essential amino acid involved in hepatic lipid export. Inositol plays a role in phospholipid synthesis. Choline supports hepatic fat metabolism and VLDL assembly. These are physiologically relevant pathways, but the clinical evidence that injecting this combination produces meaningful fat loss in humans is rated very low. No phase II or III RCT exists. Typical compounded dosing is 1 mL intramuscularly two to three times per week, but this is protocol convention, not trial-derived.

What most pages get wrong about peptide dosing

This is the section competitors skip.

1. Route of administration matters enormously for AOD-9604. Virtually every compounded protocol describes AOD-9604 as a subcutaneous injection at 250 to 300 mcg/day. The actual human clinical data comes from oral administration at much higher microgram-to-milligram doses in trials run by Metabolic Pharmaceuticals in Australia. Subcutaneous bioavailability of AOD-9604 and the dose-response relationship by that route in humans has not been published in peer-reviewed form. The SQ dose is extrapolated from animal models and anecdotal clinical experience. This does not mean the SQ dose does not work; it means no one has proven it does in a controlled human study.

2. GHRP-6 increases hunger. GHRP-6 stimulates the ghrelin receptor (GHSR-1a), and ghrelin is a known orexigenic hormone. Multiple human studies confirm that GHRP-6 administration increases appetite. Using GHRP-6 in a fat-loss cycle without controlling total caloric intake is physiologically counterproductive. Ipamorelin is selective for the GH secretagogue receptor with less ghrelin-mimetic activity and is generally preferred when appetite stimulation is undesired.

3. "Peptide cycle" implies a discrete intervention; GLP-1 agonists are not that. Many users approach semaglutide or tirzepatide like a 12-week cycle. Post-treatment data consistently show weight regain after discontinuation. The STEP 4 trial extension found that participants who stopped semaglutide regained about two-thirds of their lost weight within a year. Planning to cycle off is planning to regain weight.

4. The vial concentration is not standardized. A vial labeled "5 mg CJC-1295" from a compounding pharmacy or research source may be reconstituted to any concentration the provider chooses. A chart listing "100 mcg per injection" is useless without knowing your specific concentration. Always do your own reconstitution math (see operational section).

Chemistry: why peptide stability rules are not optional

Peptides are chains of amino acids held in shape by hydrogen bonds, disulfide bridges, and hydrophobic interactions. Several degradation pathways are relevant to weight-loss peptides:

Heat and agitation. Elevated temperature increases molecular kinetic energy, disrupting non-covalent bonds. Agitation creates air-liquid interfaces that cause surface denaturation. This is why reconstituted peptides should be gently swirled, never vortexed, and kept refrigerated. A degraded peptide does not separate visibly from a good one; it simply becomes inactive or, in worst cases, generates fragments with unknown activity.

Oxidation. Peptides containing methionine or cysteine residues are vulnerable to oxidative degradation, especially in the presence of dissolved oxygen. This is why high-quality peptide diluents are sometimes sparged with nitrogen and why some vials use inert gas headspace. Antioxidants like ascorbic acid in the same vial would theoretically help but are not standard practice in peptide compounding.

pH sensitivity. Most therapeutic peptides are stable near neutral pH (6.0 to 7.5). Bacteriostatic water sits near pH 5.5 to 6.0 due to dissolved CO2 and benzyl alcohol. This is acceptable for most peptides short-term. Mixing a peptide with a strongly acidic or alkaline co-injection (e.g., vitamin C, which is pH 2.5 to 3 in many formulations) in the same syringe can cause rapid degradation. This is the chemistry behind the rule "do not mix with ascorbic acid in the same injection."

Freeze-thaw cycling. Ice crystal formation during freezing can mechanically disrupt peptide tertiary structure. If you must freeze a reconstituted peptide (not recommended if using within 28 days), freeze once and thaw once. Multiple freeze-thaw cycles are objectively damaging.

Honest head-to-head: peptides vs. approved options

Operational label literacy: reading a COA and doing reconstitution math

What a trustworthy COA contains:

• HPLC purity: greater than 98% for research grade; labeled peak and retention time
• Mass spectrometry result: measured molecular weight matching theoretical (e.g., CJC-1295 without DAC has a theoretical MW of approximately 3,368 Da)
• Endotoxin testing by LAL (limulus amebocyte lysate) assay: should be below 1 EU per mg for injectable use
• Sterility or bioburden testing if the product is marketed as injectable
• Third-party issuing laboratory name: a COA signed by the same company selling the product has a conflict of interest

Reconstitution math:

Formula: (Vial mass in mcg) divided by (diluent volume in mL) equals concentration in mcg per mL. Dose volume in mL equals desired dose in mcg divided by concentration in mcg per mL.

Example: 5 mg (5,000 mcg) vial plus 2 mL bacteriostatic water yields 2,500 mcg per mL. To inject 250 mcg: 250 divided by 2,500 equals 0.10 mL, which is 10 units on a 100-unit insulin syringe.

Example 2: Same 5 mg vial, same dose (250 mcg), but reconstituted with 1 mL: concentration is 5,000 mcg per mL, so dose volume is 0.05 mL (5 units). The syringe markings change entirely based on your reconstitution choice. Errors here are the most common practical mistake with compounded peptides.

Signs of degradation: Cloudiness or particulates in a normally clear solution, unexpected color change, or a sharp chemical odor are warning signs. A degraded peptide should not be injected. Invisible degradation (loss of potency without visible change) is also possible and is why storage conditions are non-negotiable.

FAQ

What is a standard starting dose for CJC-1295 with DAC for fat loss?

Most clinical protocols start at 1 mg subcutaneously once or twice per week for CJC-1295 with DAC. This dose produces a sustained GH pulse lasting several days due to the drug-affinity complex. Evidence in humans is limited to small pharmacokinetic studies, not controlled fat-loss trials.

What dose of semaglutide is used for weight loss?

The approved Wegovy dosing schedule starts at 0.25 mg subcutaneously weekly for 4 weeks, escalating over 16 to 20 weeks to the maintenance dose of 2.4 mg weekly. Compounded semaglutide follows the same titration schedule but purity and concentration must be verified from the COA.

How does the lipo-C peptide dosage for weight loss work?

Lipo-C is a compounded injection combining lipotropic agents (methionine, inositol, choline) with B vitamins and sometimes carnitine. There is no standard peptide in lipo-C; the weight-loss effect attributed to it is not supported by rigorous RCT data. Doses typically range from 1 to 2 mL of a compounded solution injected intramuscularly 1 to 3 times per week.

What is the AOD-9604 dose for fat loss?

Phase II trials of AOD-9604 (Metabolic Pharmaceuticals) used oral doses of 1 mg to 54 mg daily. Subcutaneous compounded protocols often reference 250 to 300 mcg once daily in the morning, but no human RCT has confirmed fat loss at this dose by the subcutaneous route.

Is clenbuterol a peptide, and what dose is used for fat loss?

Clenbuterol is not a peptide. It is a beta-2 adrenergic agonist. It is not approved for human use in the US and carries real cardiac risk. It is included here for search clarity only. FormBlends does not endorse its use.

What peptide cycle length is recommended for fat loss?

GH secretagogue cycles in research contexts typically run 8 to 12 weeks followed by a 4 to 8 week break to limit receptor desensitization. GLP-1 agonist protocols (semaglutide, tirzepatide) are intended as continuous therapy, not cycling, under approved prescribing guidelines.

What does HGH dosage for weight loss look like in clinical trials?

Studies of exogenous recombinant HGH for fat loss in adults without GH deficiency generally used doses of 0.01 to 0.03 mg per kg per day subcutaneously. A Jorgensen et al. meta-analysis found modest reductions in fat mass but significant rates of side effects including fluid retention, arthralgia, and insulin resistance at these doses.

How do I read a peptide COA to verify dose accuracy?

A valid COA should report purity by HPLC (ideally greater than 98 percent), mass confirmation by mass spectrometry matching the expected molecular weight, and absence of endotoxin by LAL assay. If the COA lists only one test or is issued by the same company selling the product, treat it as low confidence.

Can peptides be combined in one fat loss cycle?

GHRP plus GHRH combinations (e.g., ipamorelin with CJC-1295) are commonly stacked because they act on complementary receptors to amplify GH pulse height. No human RCT exists for this stack specifically for fat loss. Adding a GLP-1 agonist to a GH secretagogue is sometimes done clinically but interaction data are absent.

What are the reconstitution volumes for common weight-loss peptides?

A vial labeled 5 mg reconstituted with 2 mL bacteriostatic water yields 2,500 mcg per mL. A 100 mcg dose then requires drawing 0.04 mL (4 units on a 100-unit insulin syringe). Always calculate based on the actual labeled vial mass and your chosen diluent volume, not a generic chart.

How should peptide vials be stored after reconstitution?

Reconstituted peptides should be refrigerated at 2 to 8 degrees Celsius and used within 28 days as a conservative limit. Freeze-thaw cycles degrade tertiary structure. Bacteriostatic water (0.9 percent benzyl alcohol) extends viable shelf life versus sterile water because it inhibits microbial growth.

Does tirzepatide outperform semaglutide for weight loss?

The SURMOUNT-1 trial of tirzepatide (Eli Lilly) showed mean body weight reductions of up to 22.5 percent at 72 weeks at the 15 mg dose. The STEP 1 trial of semaglutide 2.4 mg showed approximately 14.9 percent reduction at 68 weeks. Head-to-head data from the SURMOUNT-5 trial showed tirzepatide superior to semaglutide 2.4 mg at comparable doses.

Editorial refresh

Practical 2026 note for Peptide Dosing Chart for Weight Loss

This update makes Peptide Dosing Chart for Weight Loss more specific by tying semaglutide, tirzepatide, safety signals, weight, loss, dosage to the page's original clinical, cost, access, or comparison angle.

The goal is to make the article more useful for people who already know the headline question and need page-level specifics, not another interchangeable peptide therapy summary.

For 2026 review, the content emphasizes current verification, treatment fit, and patient-safety questions that can be discussed with a qualified provider.

Custom 2026 image for Peptide Dosing Chart for Weight Loss, peptide therapy, and better treatment decision-making.